Compare Neurocrine Biosciences Inc (NBIX) vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.13 (market cap $66.98B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 4.7× Neurocrine Biosciences Inc's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.5% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 1 Days on average.
| NBIX | NWG | |
|---|---|---|
Market Cap | $14.36B | $66.98B |
Volume | 1,237,180 | 5,259,060 |
Sector | Health | Financials |
52-Week High | $185.50 | $19.42 |
52-Week Low | $123.10 | $13.89 |
Typical Hold Time | 23 Days | 1 Days |
Enterprise Value | $14.37B | $140.55B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →
